## Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism

## SUPPLEMENTARY MATERIAL

**Supplementary figure S1.** Intragenic mosaic mutations identified by Ion AmpliSeq-Ion PGM sequencing. (A) *De novo* mosaic frameshift mutation in *NIPBL* (c.[=/7373\_7374del] p.[=/(Ser2458Cysfs\*4)] identified in individual II:1 (Family 3059) in 12% of reads in two saliva-derived DNA samples. The sequence data appeared normal in two blood-derived DNA samples from the same case. (B) Mosaic missense mutation in *NIPBL* (c.[=/6893G>A] p.[=/(Arg2298His)]) identified in individual II:1 (Family 4407) at approximately 15% and 38% in blood-derived and saliva-derived DNA samples, respectively. (C) *De novo* mosaic inframe deletion of 3 bp in *SMC1A* (c.[=/1585\_1587del] p.[=/(Lys529del)]) identified at significantly different levels (53% and 10%) in two saliva-derived DNA samples from individual II:1 (Family 3176) collected at ages of 14.3 and 18.3 years, respectively. Mutations are marked by blue blocks along the sequence reads. Sequence traces were obtained from NextGENe software v.2.3.3 (Soft Genetics).



## A Family 3059 (NIPBL c.[=/7373\_7374del] p.[=/(Ser2458Cysfs\*4)] de novo)

В

**Supplementary figure S2.** Genome-wide array CGH analysis of mutation-negative cases. (A) *De novo* heterozygous deletion of 1.3Mb is marked along chromosome 1 (red arrow) in data analysed in Pat ID 3076 (arr 1p36.33 (984,137-2,284,140; hg19)). The results show absence of the deletion in both parents (Fam ID 3076). (B) Heterozygous duplication of 520 kb is marked (blue arrow) on array CGH data from chromosome 12 in Pat ID 3040 (arr 12q13.13 (53,582,733-54,102,733; hg19)). Black dots represent the segmented probes along each chromosome. Log<sub>2</sub> ratio (case:control) is shown on the y-axis and the genomic context is represented along the x-axis using the software programme Signal Map (Roche Nimblegen). (C) The duplication of *ESPL1* was confirmed using a TaqMan CNV assay and compared to seven control samples with either known intragenic causative mutations in another gene (C1-C3) or normal *ESPL1* copy number based on whole-exome data (C4-C7). Genomic copy number, calculated as  $2^{\Delta\Delta Ct}$ , is shown on the y-axis. Analysis was carried out in triplicate using the software Copy Caller v1.0 (Applied Biosystems).





4

**Supplementary figure S3.** Developmental milestones for individuals with mutations in *NIPBL, SMC1A, SMC3, HDAC8, RAD21, ANKRD11*, CNV, and for those without a mutation identified. Ages at which each developmental milestone was reached is shown on the y-axis in months. The number of cases with available growth data in each genotype category is shown at the bottom of each box-plot. The width of each box-plot is proportional to the number of cases in each category. The line in the middle of each box is the median. The bottom and top of each box represent the 25<sup>th</sup> and 75<sup>th</sup> centiles, respectively. The whiskers represent the 95<sup>th</sup> centile (if normally distributed) or the minimum/maximum data points. Outlier values are shown by circles.



**Supplementary figure S4.** Box-plots of pre- and post-natal growth for each of the gene categories (*NIPBL*, *SMC1A*, *SMC3*, *HDAC8* and *RAD21*), chromosomal rearrangements (CNV) and those without an identifiable mutation (no\_mutation). Box-plots are coloured in red for prenatal growth and purple for postnatal growth. Z scores were calculated using the British Growth Survey data, adjusted for sex and age. The number of cases in each category is shown below the box-plot. BL, birth length; Ht, height; BWt, birth weight; Wt, weight; BOFC, head circumference at birth; OFC, head circumference.







Supplementary table S1. Type and number of mutations identified in a cohort of 163

affected individuals from whom DNA was available (including mosaic mutations)

Gene and mutation type	Number of mutations (%)			
NIPBL				
	Nonsense	12 (7.4%)		
	Frameshift	9 (5.5%)		
	Splice site	8 (4.9%)		
	Missense*	16 (9.8%)		
	Genomic loss/gain	1 (0.6%)†		
	Total	46 (28.2%)		
SMC1A				
	Nonsense	-		
	Frameshift	-		
	Splice site	-		
	Missense*	5 (3.1%)		
	Genomic loss/gain	-		
	Total	5 (3.1%)		
SMC3				
	Nonsense	1 (0.6%)		
	Frameshift	-		
	Splice site	-		
	Missense*	4 (2.5%)		
	Genomic loss/gain	-		
	Total	5 (3.1%)		
HDAC8				
	Nonsense	-		
	Frameshift	-		
	Splice site	-		
	Missense*	3 (1.8%)§		
	Genomic loss/gain	3 (1.8%)§		
	Total	6 (3.6%)		
RAD21				
	Nonsense	-		
	Frameshift	-		
	Splice site	1 (0.6%)		
	Missense*	-		
	Genomic loss/gain	-		
	Total	1 (0.6%)		

\* Includes in-frame insertion/deletions

† Murray *et al*. (2012)

§ Kaiser et al. (2014)

Supplementary table S2. Summary of whole-exome sequencing results from five unrelated

CdLS and CdLS-like cases

Patient ID	3060	3061	3051	3041	3024
Mean depth	260X	276X	252X	237X	283X
Reads on target	53%	49%	51%	67%	47%
Total number of SNVs (% in	2346262	2710305	2434134	1116837	2432647
dbSNP131)	(91%)	(91%)	(91%)	(86%)	(91%)
Total number of indels (%	103260	140495	108481	44526	102501
in dbSNP131)	(14%)	(14%)	(14%)	(12%)	(14%)
Filtered* non-synonymous					
coding	1146	1105	1072	1566	924
Filtered* stop gained	59	50 <sup>¥</sup>	54	73	53
Filtered* frameshift coding	665	679	627	683 <sup>∞</sup>	427
Filtered* essential splice					
site	14	16	24	33	18

\* Not in dbSNP131, 1000 Genomes Pilot projects 1,2,3 or release 2010-08-04, 8 HapMap exomes, or 10 Kabuki syndrome exomes;

¥ contains the mosaic *NIPBL* nonsense mutation, c.[=/1435C>T] p.[=/(Arg479\*)];

∞ Contains the ANKRD11 c.6210\_211del p.(Lys2070Asnfs\*31) frameshift mutation;

SNV, single nucleotide variant; indel, insertion/deletion

		Z score birth	Z score birth	Z score birth head	7	7	Z score head	Mean Gestalt	Mean Severity
		length* [95% C.I.]	weight* [95% C.I.]	circumference*		Z score weight*	circumference*	score†	score
		(N)	(N)	[95% C.I.] (N)	[95% C.I.] (/v)	[95% C.I.] (/V)	[95% C.I.] ( <i>N</i> )	[95% C.I.] ( <i>N</i> )	[95% C.I.] ( <i>N</i> )
		-2.59 [-5.72 to	-2.32 [-2.76 to -	-3.88 [-5.53 to -	-3.68 [-4.45 to -	-3.91 [-4.67 to -	-5.14 [-5.74 to -	7.42 [6.77 to	19.63 [16.85 to
NIPBL (all)		0.55] (4)	1.88] (38)	2.23] (4)	2.91] (23)	3.15] (27)	4.53] (27)	8.08] (28)	22.41] (34)
	nonsense/fr		-2.43 [-3.31 to -		-4.52 [-6.36 to -	-4.39 [-5.93 to -	-5.86 [-6.69 to -	7.71 [6.79 to	20.79 [16.54 to
	ameshift	-	1.54] (17)	-3.07 [NA] (1)	2.68] (7)	2.84] (10)	5.04] (10)	8.63] (11)	25.03] (16)
			-3.21 [-4.14 to -		-3.99 [-6.09 to -	-3.88 [-6.63 to -	-5.27 [-7.64 to -	8.39 [7.15 to	23.56 [14.26 to
	splice site	-4.93 [NA] (1)	2.27] (6)	-5.30 [NA] (1)	1.90] (5)	1.13] (6)	2.89] (6)	9.63] (6)	32.85] (7)
		-1.80 [-5.44 to	-1.88 [-2.27 to -	-3.58 [-9.04 to 1.88]	-3.29 [-4.19 to -	-3.49 [-4.35 to -	-4.39 [-5.24 to -	6.70 [5.27 to	15.80 [12.39 to
	Missense	1.83] (3)	1.48] (14)	(2)	2.38] (10)	2.64] (11)	3.53] (10)	8.13] (10)	19.21] (10)
	Genomic								
	loss/gain	-	-1.33 [NA] (1)	-	-0.06 [NA] (1)	-	-4.57 [NA] (1)	5.67 [NA] (1)	12.00 [NA] (1)
			-1.23 [-2.08 to -		-1.79 [-3.28 to -	0.30 [-2.61 to	-3.56 [-13.31 to	4.72 [2.37 to	13.88 [8.79 to
SMC1A		-	0.38] (4)	-2.36 [NA] (1)	0.31] (3)	3.21] (3)	6.19] (3)	7.08] (3)	18.97] (5)
					-2.41 [-3.89 to -	-2.10 [-4.33 to	-4.02 [-7.54 to -	5.20 [2.13 to	
SMC3		-	-1.04 [NA] (1)	-	0.92] (5)	0.13] (5)	0.49] (5)	8.27] (5)	10.70 [NA] (1)
		-2.04 [-6.11 to	-2.65 [-4.94 to -	-2.87 [-4.62 to -	-2.71 [-3.46 to -	-1.82 [-3.09 to -	-3.52 [-5.01 to -	5.20 [2.88 to	18.37 [14.43 to
HDAC8		2.03] (2)	0.35] (4)	1.12] (3)	1.96] (6)	0.53] (5)	2.02] (6)	7.52] (5)	22.32] (4)
RAD21		-	-	-	-0.97 [NA] (1)	-1.83 [NA] (1)	-4.71 [NA] (1)	-	-
			-1.56 [-20.37 to		-1.15 [-4.62 to	-0.18 [-3.22 to	-0.68 [-3.13 to	4.78 [2.87 to	15.20 [5.03 to
ANKRD11		-	17.25] (2)	-	2.32] (3)	2.87] (3)	1.76] (3)	6.69] (3)	25.36] (2)
Genomic									
rearrangem									
ents		-1.19 [NA] (1)	-2.07 [NA] (1)	-	-2.29 [NA] (1)	-0.41 [NA] (1)	-2.90 [NA] (1)	5.67 [NA] (1)	24.00 [NA] (1)
No		-3.33 [-16.86 to	-2.02 [-2.46 to -	-3.51 [-4.57 to -	-2.37 [-2.72 to -	-2.18 [-2.78 to -	-3.63 [-4.17 to -	5.63 [5.11 to	17.73 [15.84 to
mutation		10.21] (2)	1.57] (58)	2.46] (8)	2.02] (56)	1.58] (55)	3.10] (57)	6.15] (53)	19.63] (48)

Supplementary table S3. Genotype-phenotype correlations in unrelated cases of CdLS

\* Z scores obtained using the British Growth Survey data; *N*, number of individuals; C.I., confidence interval of the mean; NA, not applicable

Supplementary table S4. Structural anomalies in individuals with an identified mutation.

System	Gene	Mutation type	Details
Cardiac	NIPBL	Splice	PFO; pulmonary valve stenosis
		Truncating	PFO
		Truncating	pulmonary artery stenosis
		Truncating	ASD; VSD
		Truncating	ASD; VSD; PDA
		Truncating	ASD; VSD
	HDAC8		ASD; VSD
			ASD
	SMC1A		bicuspid aortic valve
Limb reduction defects	NIPBL	Splice	phocomelia right arm; micromelia left arm with one digit missing
		Splice	
		Truncating	absent ulna; left hand has thumb and index finger only
		Truncating	right single digit; left four digits; single bone in right forearm
		Truncating	
		Truncating	
		Missense	bilateral thumb hypoplasia
Gastrointestinal	NIPBL	Missense	tracheoesophageal fistula
		Splice	pyloric stenosis
		Truncating	pyloric stenosis
		Truncating	malrotation
	SMC3		volvulus on two occasions
Ocular	NIPBL	Truncating	myopia -2 dioptres
		Truncating	cataract

PFO = patent foramen ovale, ASD = atrial septal defect, VSD = ventricular septal defect, PDA = patent ductus arteriosus.